Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 4, 2023, Göran A. Ando, M.D., a member of the Board of Directors (the "Board") of Selecta Biosciences, Inc. (the "Company"), notified the Company that he is retiring from the Company's Board effective immediately. Prior to his retirement, Dr. Ando served on the Board's Compensation and Research and Development Committees, and will cease service on each committee in connection with his retirement. Dr. Ando's retirement was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Dr. Ando has been a valued member of the Company's Board since April 2020, providing exemplary service and many important contributions to the Company during his tenure on the Board. The Company thanks Dr. Ando for his advice and leadership as a member of the Company's Board and wishes Dr. Ando well in his retirement.

Item 7.01. Regulation FD Disclosure.

On January 9, 2023, the Company issued a press release announcing certain information relating to its business. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

On January 9, 2023, the Company issued a press release announcing certain information relating to its business. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.2. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.

Additionally, the Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.3. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.3.

The information in Item 7.01 of this Form 8-K, including Exhibit 99.1, Exhibit 99.2, and Exhibit 99.3 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


    Exhibit
      No.                                              Description

      99.1                Press Release Issued on January 9, 2023
      99.2                Press Release Issued on January 9, 2023
      99.3                Corporate slide presentation of Selecta Biosciences, Inc. dated January
                        2023
      104               Cover Page Interactive Data File (embedded within the Inline XBRL
                        document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses